Publication Name	World Journal of Clinical Cases
Manuscript ID	119781
Country	Japan

Category	Gastroenterology & Hepatology
Manuscript Type	Case Report
Article Title	Dramatic response to fourth-line ramucirumab after atezolizumab plus bevacizumab failure in advanced hepatocellular carcinoma: A case report
Manuscript Source	Invited Manuscript
All Author List	Masanori Fukushima, Yasuhiko Nakao, Ryu Sasaki, Masafumi Haraguchi, Satoshi Miuma and Hisamitsu Miyaaki
Funding Agency and Grant Number
Corresponding Author	Masanori Fukushima, Department of Gastroenterology and Hepatology,, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1, Nagasaki 8528501, Japan. ma-fukushima@nagasaki-u.ac.jp
Key Words	Alpha-fetoprotein; Atezolizumab plus bevacizumab; Child-Pugh B; Hepatocellular carcinoma; Later-line therapy; Ramucirumab; Tyrosine kinase inhibitor intolerance; Case report
Core Tip	Hepatocellular carcinoma with elevated alpha-fetoprotein levels that progresses following atezolizumab plus bevacizumab administration may involve enhanced vascular endothelial growth factor receptor-2 signaling, making ramucirumab a potentially effective treatment option.
Citation	Fukushima M, Nakao Y, Sasaki R, Haraguchi M, Miuma S, Miyaaki H. Dramatic response to fourth-line ramucirumab after atezolizumab plus bevacizumab failure in advanced hepatocellular carcinoma: A case report. World J Clin Cases 2026; In press

Received	2026-02-24 07:32
Peer-Review Started	2026-02-24 07:32
First Decision by Editorial Office Director	2026-03-02 08:48
Return for Revision	2026-03-02 08:48
Revised	2026-03-13 01:32
Publication Fee Transferred
Second Decision by Editor	2026-04-08 02:40
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-04-08 03:51
Articles in Press	2026-04-08 03:51
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2307-8960 (online)
Open Access	This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright	©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com